Esperion Therapeutis.Inc. buy Quitte
Start price
20.01.16
/
50%
€14.56
Target price
21.07.16
€17.50
Performance (%)
-32.35%
End price
21.07.16
€9.85
Summary
This prediction ended on 21.07.16 with a price of €9.85. The BUY prediction by Quitte for Esperion Therapeutis.Inc. performed very badly with a performance of -32.35%. Quitte has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -14.901% | -14.901% | 20.550% | -59.066% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% | 63.672% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% | 109.562% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% | 54.912% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% | 69.801% |
Comments by Quitte for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Jammertal ade
irgendwann muss das was werden
(Laufzeit überschritten)